Association of carbamylated high-density lipoprotein with coronary artery disease in type 2 diabetes mellitus: carbamyla
- PDF / 3,373,283 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 31 Downloads / 243 Views
Journal of Translational Medicine Open Access
RESEARCH
Association of carbamylated high‑density lipoprotein with coronary artery disease in type 2 diabetes mellitus: carbamylated high‑density lipoprotein of patients promotes monocyte adhesion Zhongli Chen1†, Song Ding2†, Yan Ping Wang1†, Liang Chen3, Jing Yan Mao2, Ying Yang4, Jia Teng Sun2* and Ke Yang1*
Abstract Background: Increasing evidence showed that carbamylated lipoprotein accelerated atherosclerosis. However, whether such modification of high-density lipoprotein (HDL) particles alters in type 2 diabetes mellitus (T2DM) patients and facilitates vascular complications remains unclear. We aimed to investigate the alteration of the carbamylation in HDL among T2DM patients and clarify its potential role in atherogenesis. Methods: A total of 148 consecutive T2DM patients undergoning angiography and 40 age- and gender-matched control subjects were included. HDL was isolated from plasma samples, and the concentration of HDL carbamyl-lysine (HDL-CBL) was measured. Furthermore, the HDL from subjects and in-vitro carbamylated HDL (C-HDL) was incubated with endothelial cells and monocyte to endothelial cell adhesion. Adhesion molecule expression and signaling pathway were detected. Results: Compared with the control group, the HDL-CBL level was remarkably increased in T2DM patients (6.13 ± 1.94 vs 12.00 ± 4.06 (ng/mg), P
Data Loading...
